The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- US FDA Approves Velcade Retreatment in Patients with Multiple Myeloma: Takeda
August 12, 2014
- Astellas Ties Up with Cancer Research UK for Joint Research for Cancer Treatments
August 12, 2014
- Asahi Kasei Pharma Aims to Achieve Sales Target of 100 Billion Yen in FY2015 Despite Debut of Flivas Generics: President
August 11, 2014
- University of Tokyo, Fujitsu, Kowa Discover Novel Anticancer Drug Candidate through IT-Based Drug Discovery Technology
August 11, 2014
- Kowa Files Livalo for Pediatric Indication
August 11, 2014
- Sanofi Files NDA for Hydroxychloroquine
August 11, 2014
- Sumitomo Dainippon Reexamining Midterm Plan Due to Halt of BBI608 Study
August 8, 2014
- JPWA Members Still on Recovery Track with 0.88% Operating Margin in FY2013
August 8, 2014
- Half of Member Companies Report Price Settlements: Qol-Led Open Tender
August 8, 2014
- Linical Aims to Become “One-Stop” CRO for Global Clinical Trials
August 8, 2014
- Daiichi Sankyo Collaborates with US Venture for Analgesic in the US
August 8, 2014
- Daiwa Corporate Investment Establishes Venture Capital Firm Specializing in Biopharmaceuticals; Sights Set on Seeds of University Origin
August 7, 2014
- Development of Material for Treating Cartilage Injury Selected by NexTEP: Mochida
August 7, 2014
- Kyowa Kirin’s UK Subsidiary Completes Acquisition of Archimedes Pharma
August 7, 2014
- Santen Includes FY2017 Sales Target of 205 Billion Yen and Globalization in New Business Plan
August 6, 2014
- ASKA to Launch Blopress AGs on Sept 12
August 6, 2014
- Hisamitsu to Dissolve US JV with Novartis Pharmaceuticals
August 6, 2014
- Eli Lilly Japan Files NDA for GLP-1 Receptor Agonist Dulaglutide
August 6, 2014
- Eisai Ends Development of Diabetic Complication Treatment
August 5, 2014
- Development of Antibody Drugs Accelerating in the Field of Asthma; First New Option Could Be Available as Early as 2016
August 5, 2014
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…